PCM
TEVA icon

Poehling Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Poehling Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Buy
+6,499
New +$216K 0.05% 154
2018
Q3 		– Sell
-2,500
Closed -$61K – 240
2018
Q2 		$61K Hold
2,500
– – 0.05% 135
2018
Q1 		$43K Hold
2,500
– – 0.03% 158
2017
Q4 		$47K Buy
+2,500
New +$37.6K 0.04% 150

Other funds holding TEVA

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
BCM
Bourgeon Capital Management Darien, Connecticut $679M AUM 50.89% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Poehling Capital Management's TEVA Position: Q2 2026 in Review

Poehling Capital Management opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 6,499 shares worth $220K. The stake represents 0.05% of the portfolio and ranks #154 among its holdings. This is a return to the name: Poehling Capital Management previously reported a position in TEVA as recently as Q2 2018.

Poehling Capital Management first reported a position in TEVA in Q4 2017 and has held it in 4 quarters since. 130 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Poehling Capital Management held 6,499 shares of Teva Pharmaceuticals worth $220K as of Q2 2026.
  • Teva Pharmaceuticals was a new Poehling Capital Management position in Q2 2026.
  • Teva Pharmaceuticals made up 0.05% of Poehling Capital Management's portfolio in Q2 2026, its #154 holding.
  • Poehling Capital Management first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 4 quarters since.
  • 130 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Poehling Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.